BioNTech’s Sean Marett explains Genentech deal rationale

November 24, 2016 Christoph Graener

Chief operating officer of BioNTech, Sean Marett, talks to Mike Ward, global director of content for Informa Pharma Intelligence, about the German firm’s recent co-development deal with Roche company, Genentech. On the sidelines of the recent BIO-Europe® partnering conference, held in Cologne Germany, Marett outlines the benefits of this collaboration, such as access to the US market and regulatory expertise. This deal will be highlighted as part of a deal case study session at The One Nucleus Genesis meeting in London on December 1, 2016.

  

  

Interviewer: Mike Ward – Global Director of Content, Informa Pharma Insights
Interviewee: Sean Marett – COO, BioNTech

 

Previous Article
eTheRNA CEO outlines development plan in cancer RNA space
eTheRNA CEO outlines development plan in cancer RNA space

Mike Ward interviews Dirk Reyn, CEO of eTheRNA, discussing eTheRNA's emerging cancer immunotherapy pipeline...

Next Article
AiCuris seeks partners for antibacterial programs
AiCuris seeks partners for antibacterial programs

AiCuris CEO Holger Zimmermann talks about the company's journey to becoming a clinical biotech company sinc...